Aditxt Reports Significant Revenue Decline and Increased Net Loss in Q2 2025

Aditxt, Inc. reported a significant decline in financial performance for the second quarter of 2025, with revenues dropping to $1,004 compared to $44,276 in the same period last year. For the first half of 2025, total revenue was $2,022, down from $123,956 in the first half of 2024. The decrease in revenue is attributed to a reduction in orders for the AditxtScore™ platform, primarily due to a decline in COVID-19 testing. The company incurred a net loss of $7,395,658 for the quarter, slightly less than the $7,623,879 loss reported in the prior year, while the six-month net loss totaled $13,348,123, a decrease from $22,492,573 in the same period last year.

In terms of operational changes, Aditxt has been actively pursuing strategic initiatives, including the acquisition of patents through its subsidiary Pearsanta, which aims to develop molecular tests for early cancer detection. The company also engaged in a merger agreement with Evofem Biosciences, although the completion of this transaction remains uncertain. As of June 30, 2025, Aditxt's cash reserves stood at $323,679, a significant decrease from $833,031 at the end of 2024, raising concerns about its ability to fund ongoing operations and clinical studies.

The company’s total liabilities decreased to $20,696,368 from $23,857,994 at the end of 2024, primarily due to a reduction in accounts payable and accrued expenses. However, Aditxt's working capital remains negative at $(20,148,964), indicating ongoing financial strain. The company has also reported a substantial accumulated deficit of $181,061,686 as of June 30, 2025. Aditxt's employee headcount and customer engagement metrics were not disclosed in the filing, but the company continues to focus on its research and development efforts, albeit at a reduced scale.

Looking ahead, Aditxt has expressed concerns about its ability to continue as a going concern, emphasizing the need for significant additional capital to sustain operations and fund clinical trials. The company is exploring various financing options, including equity and debt offerings, but acknowledges that market conditions may impact its ability to raise funds. Aditxt's management remains focused on executing its business plan and addressing the challenges posed by its current financial situation, while also pursuing potential partnerships and collaborations to enhance its product development pipeline.